OPN is excited that the FDA has granted breakthrough status to Dizal’s Sunvozertinib as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). OPN is offering access to this breakthrough product by enrolling patients in this DZ2022E0005 trial. This study now open and accruing to gain full FDA approval.
The FDA’s Breakthrough Therapy designation expedites “the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).”1
For more information on all OPN managed clinical trials, please visit our active clinical trials web page.